Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sarepta gene therapy study shows promise

Sarepta Therapeutics shares jumped 60 percent after reporting promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).

Read More »

Denying it has lost war on drugs, UK rules out legalizing cannabis

Britain said it had no intention of legalizing cannabis after a former leader of Prime Minister Theresa May’s party said the government had “irreversibly lost” the battle to drive the drug off the streets.

Read More »

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Read More »

Soaring costs, loss of benefits top Americans’ healthcare worries: Reuters/Ipsos poll

Americans listed healthcare as the most important problem facing the country, according to Reuters/Ipsos polling.

Read More »

FDA declines to approve Valeant’s plaque psoriasis lotion

Valeant Pharmaceuticals International Inc.’s plaque psoriasis treatment did not get approval from U.S. health regulators.

Read More »

DreaMed Receives FDA Approval for Diabetes Management Software

The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.

Read More »

Gaming addiction classified as mental health disorder by WHO

Addiction to video games has been recognized by the World Health Organization as a mental health disorder.

Read More »

Theranos founder Holmes, former president indicted for fraud

Theranos Inc. founder Elizabeth Holmes and the embattled blood-testing company’s former president were indicted on charges that they engaged in schemes to defraud investors, doctors and patients, the U.S. Justice Department announced.

Read More »

Teva to discontinue study for chronic headache treatment

Teva Pharmaceutical Inc. will discontinue a trial testing the company’s drug for the treatment of chronic cluster headache.

Read More »

New research points to universal antibody drug for HIV

AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.

Read More »

Novartis touts effectiveness, safety of autoimmune drug copies

Novartis touted safety and efficacy of the company’s biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel for treating autoimmune diseases.

Read More »

Kentucky sues Walgreens Boots Alliance

Kentucky’s attorney general sued Walgreens Boots Alliance Inc., accusing the company of playing a role in propagating an opioid epidemic in the state.

Read More »

GSK’s two-drug HIV treatment meets studies’ main goal

GlaxoSmithKline’s two-drug treatment for HIV met its main goal in late-stage studies, scoring key points in the company’s rivalry with Gilead in the medical field.

Read More »

FDA finds deficiencies in Mylan’s generic Advair

Mylan NV said U.S. health regulators were unable to approve the company’s generic version of GlaxoSmithKline’s blockbuster inhaled lung drug Advair for the second time, as they found “minor deficiencies” in the treatment.

Read More »

Lilly’s lupus treatment succeeds in mid-stage trial

Eli Lilly and Co. said the company’s drug to treat the autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a larger study in 2018.

Read More »

Sanofi says company on track to regain solid position in cancer drugs

Sanofi believes that it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Read More »

J&J accepts $2.1 billion offer for LifeScan unit

Johnson & Johnson has accepted private equity firm Platinum Equity’s $2.1 billion buyout offer for the company’s LifeScan unit.

Read More »

‘We are still at war’ with Ebola: WHO chief

The head of the World Health Organization cautioned against declaring victory too early in Congo’s Ebola epidemic, despite encouraging signs that it may be brought under control.

Read More »

Lilly-AstraZeneca abandon Alzheimer’s drug trials

Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Read More »

Galmed gets positive trial results for liver drug

Galmed Pharmaceuticals said patients in a mid-stage trial for the company’s treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation